BRPI0407662A - derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas - Google Patents
derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativasInfo
- Publication number
- BRPI0407662A BRPI0407662A BRPI0407662-1A BRPI0407662A BRPI0407662A BR PI0407662 A BRPI0407662 A BR PI0407662A BR PI0407662 A BRPI0407662 A BR PI0407662A BR PI0407662 A BRPI0407662 A BR PI0407662A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- acid derivatives
- neurodegenerative diseases
- phenylalkanecarboxylic acid
- phenylalkanecarboxylic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
- C07C15/12—Polycyclic non-condensed hydrocarbons
- C07C15/14—Polycyclic non-condensed hydrocarbons all phenyl groups being directly linked
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/62—Halogen-containing esters
- C07C69/65—Halogen-containing esters of unsaturated acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
- C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/62—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/16—Unsaturated compounds
- C07C61/40—Unsaturated compounds containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI20030311 ITMI20030311A1 (it) | 2003-02-21 | 2003-02-21 | Acidi 2-fenil-2-dialchil-acetici per il trattamento della malattia di alzheimer. |
ITMI20032068 ITMI20032068A1 (it) | 2003-10-23 | 2003-10-23 | Derivati dell'acido 1-fenilcicloalcancarbossilico per il trattamento delle malattie neurodegenerative. |
PCT/EP2004/001596 WO2004074232A1 (en) | 2003-02-21 | 2004-02-19 | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0407662A true BRPI0407662A (pt) | 2006-03-01 |
BRPI0407662B1 BRPI0407662B1 (pt) | 2019-11-12 |
BRPI0407662B8 BRPI0407662B8 (pt) | 2021-05-25 |
Family
ID=32910543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0407662A BRPI0407662B8 (pt) | 2003-02-21 | 2004-02-19 | derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas |
Country Status (17)
Country | Link |
---|---|
US (3) | US7662995B2 (pt) |
EP (1) | EP1594833B1 (pt) |
JP (1) | JP4472691B2 (pt) |
KR (2) | KR101152448B1 (pt) |
AT (1) | ATE409176T1 (pt) |
AU (1) | AU2004213145B2 (pt) |
BR (1) | BRPI0407662B8 (pt) |
CA (1) | CA2514384C (pt) |
CY (1) | CY1108514T1 (pt) |
DE (1) | DE602004016729D1 (pt) |
DK (1) | DK1594833T3 (pt) |
ES (1) | ES2312964T3 (pt) |
HK (1) | HK1087398A1 (pt) |
NO (1) | NO333118B1 (pt) |
PT (1) | PT1594833E (pt) |
SI (1) | SI1594833T1 (pt) |
WO (1) | WO2004074232A1 (pt) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1284729A4 (en) * | 2000-04-13 | 2007-12-19 | Mayo Foundation | REDUCTION AGENTS OF A (BETA) 42 |
WO2004071431A2 (en) * | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
BRPI0407662B8 (pt) * | 2003-02-21 | 2021-05-25 | Chiesi Farm Spa | derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas |
US20050042284A1 (en) * | 2003-07-11 | 2005-02-24 | Myriad Genetics, Incorporated | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease |
US20070293538A1 (en) * | 2004-04-13 | 2007-12-20 | Myriad Genetics, Incorporated | Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders |
US20050252144A1 (en) * | 2004-04-29 | 2005-11-17 | Macdonald Robert A | Veneers for walls, retaining walls and the like |
JP4866851B2 (ja) | 2004-08-03 | 2012-02-01 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 神経変性疾患の処置のための1−フェニルアルカンカルボン酸の誘導体 |
WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020853A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
CA2615063A1 (en) * | 2005-07-22 | 2007-02-01 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
EP2046119A2 (en) * | 2006-07-07 | 2009-04-15 | Myriad Genetics, Inc. | Treatment of psychiatric disorders |
JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
RU2527177C2 (ru) | 2007-12-20 | 2014-08-27 | Энвиво Фармасьютикалз, Инк. | Четырехзамещенные бензолы |
EP2133322A1 (en) * | 2008-06-11 | 2009-12-16 | CHIESI FARMACEUTICI S.p.A. | Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid |
SG178239A1 (en) * | 2009-08-04 | 2012-03-29 | Chiesi Farma Spa | Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid |
EP2531511A1 (en) | 2010-02-03 | 2012-12-12 | Infinity Pharmaceuticals, Inc. | Fatty acid amide hydrolase inhibitors |
EP2647618A1 (en) * | 2010-04-01 | 2013-10-09 | CHIESI FARMACEUTICI S.p.A. | Novel polymorphs and salts |
EP2560942B1 (en) | 2010-04-21 | 2014-11-26 | Chiesi Farmaceutici S.p.A. | 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis |
EP2575797A1 (en) * | 2010-06-04 | 2013-04-10 | Chiesi Farmaceutici S.p.A. | 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases |
US9592210B2 (en) | 2011-12-22 | 2017-03-14 | Chiesi Farmaceutici S.P.A. | 1-phenylalkanecarboxylic acid derivatives for the treatment of cognitive impairment |
WO2013150072A1 (en) | 2012-04-04 | 2013-10-10 | Chiesi Farmaceutici S.P.A. | Derivatives of 1-(2-halo-biphenyl-4-yl)- alkanecarboxylic acids for the treatment of neurodegenerative diseases |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
EP2818460A1 (en) | 2013-06-24 | 2014-12-31 | ZaCh System S.p.A. | Cyclopropanation of substituted phenylacetonitriles or phenyl acetates |
TR201809263T4 (tr) | 2013-06-24 | 2018-07-23 | Chiesi Farm Spa | 1-(2-floro[1,1'-bi̇feni̇l]-4-yl)-si̇klopropankarboksi̇li̇k asi̇t türevleri̇ni̇n hazirlanmasi i̇çi̇n i̇yi̇leşti̇ri̇lmi̇ş proses |
WO2015109109A1 (en) | 2014-01-15 | 2015-07-23 | Forum Pharmaceuticals Inc. | Fused morpholinopyrimidines and methods of use thereof |
US20150320706A1 (en) | 2014-05-12 | 2015-11-12 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
US20150335596A1 (en) | 2014-05-26 | 2015-11-26 | Chiesi Farmaceutici S.P.A. | 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the treatment of down's syndrome |
US9802927B2 (en) | 2015-06-10 | 2017-10-31 | Denali Therapeutics, Inc. | Oxadiazine compounds and methods of use thereof |
IL310956A (en) | 2021-08-31 | 2024-04-01 | Cerespir Incorporated | common crystal |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE735385A (pt) * | 1968-07-04 | 1969-12-01 | ||
JPS4994680A (pt) | 1973-01-22 | 1974-09-09 | ||
JPS5046669A (pt) * | 1973-03-28 | 1975-04-25 | ||
JPS58177977A (ja) * | 1982-04-09 | 1983-10-18 | Grelan Pharmaceut Co Ltd | 4−フエニルピラゾ−ル類 |
WO1996002529A1 (fr) * | 1994-07-13 | 1996-02-01 | Taisho Pharmaceutical Co., Ltd. | Derive de l'acide thiophene acetique |
JPH0994680A (ja) * | 1995-07-24 | 1997-04-08 | Toyota Motor Corp | 摩擦圧接装置 |
US5994379A (en) | 1998-02-13 | 1999-11-30 | Merck Frosst Canada, Inc. | Bisaryl COX-2 inhibiting compounds, compositions and methods of use |
EP1284729A4 (en) | 2000-04-13 | 2007-12-19 | Mayo Foundation | REDUCTION AGENTS OF A (BETA) 42 |
EP1587798A4 (en) * | 2003-01-14 | 2007-06-27 | Merck & Co Inc | NSAID DERIVATIVES WITH GEMINAL DISUBSTITUTION AS ABETA REDUCING AGENTS 42 |
BRPI0407662B8 (pt) * | 2003-02-21 | 2021-05-25 | Chiesi Farm Spa | derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas |
JP4866851B2 (ja) * | 2004-08-03 | 2012-02-01 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 神経変性疾患の処置のための1−フェニルアルカンカルボン酸の誘導体 |
EP2133322A1 (en) * | 2008-06-11 | 2009-12-16 | CHIESI FARMACEUTICI S.p.A. | Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid |
-
2004
- 2004-02-19 BR BRPI0407662A patent/BRPI0407662B8/pt not_active IP Right Cessation
- 2004-02-19 AT AT04712483T patent/ATE409176T1/de active
- 2004-02-19 SI SI200430900T patent/SI1594833T1/sl unknown
- 2004-02-19 JP JP2006501896A patent/JP4472691B2/ja not_active Expired - Lifetime
- 2004-02-19 WO PCT/EP2004/001596 patent/WO2004074232A1/en active IP Right Grant
- 2004-02-19 CA CA2514384A patent/CA2514384C/en not_active Expired - Fee Related
- 2004-02-19 ES ES04712483T patent/ES2312964T3/es not_active Expired - Lifetime
- 2004-02-19 DK DK04712483T patent/DK1594833T3/da active
- 2004-02-19 PT PT04712483T patent/PT1594833E/pt unknown
- 2004-02-19 KR KR1020117008239A patent/KR101152448B1/ko active IP Right Grant
- 2004-02-19 AU AU2004213145A patent/AU2004213145B2/en not_active Ceased
- 2004-02-19 US US10/546,190 patent/US7662995B2/en active Active
- 2004-02-19 EP EP04712483A patent/EP1594833B1/en not_active Expired - Lifetime
- 2004-02-19 DE DE602004016729T patent/DE602004016729D1/de not_active Expired - Lifetime
- 2004-02-19 KR KR1020057014850A patent/KR101088272B1/ko active IP Right Grant
-
2005
- 2005-08-18 NO NO20053855A patent/NO333118B1/no not_active IP Right Cessation
-
2006
- 2006-07-07 HK HK06107643.0A patent/HK1087398A1/xx not_active IP Right Cessation
-
2008
- 2008-11-14 CY CY20081101310T patent/CY1108514T1/el unknown
-
2009
- 2009-12-24 US US12/647,069 patent/US8022250B2/en not_active Expired - Lifetime
-
2011
- 2011-08-08 US US13/204,989 patent/US8314268B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0407662B8 (pt) | derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas | |
DOP2002000429A (es) | Imidazotriazinas | |
WO2007038459A3 (en) | Carboxyamine compounds and their use in the treatment of hdac dependent diseases | |
WO2006035237A3 (en) | Methods and compositions relating to alzheimer's disease | |
ES2414872T8 (es) | Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente | |
WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
IN2005DE03350A (pt) | ||
EP2213684A3 (en) | Nogo-a antibodies for the treatment of Alzheimer disease | |
WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
HK1092467A1 (en) | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n- | |
WO2005032471A3 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2004062625A3 (en) | Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease | |
UA85559C2 (en) | Aminobenzophenone compounds | |
UY27993A1 (es) | Derivados de 4-pirrolidino-fenil-bencil eter | |
WO2005018545A3 (en) | Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease | |
BR0318278A (pt) | compostos de éter aminocicloexìlico e usos dos mesmo | |
HK1104280A1 (en) | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases | |
WO2007017146A3 (en) | Use of collismycin and derivatives thereof as oxidative stress inhibitors | |
WO2005080549A3 (de) | Trioxacarcine und deren verwendung gegen infektionskrankheiten | |
WO2007048034A3 (en) | Use of androgens for the treatment of parkinson' s disease | |
BRPI0509881A (pt) | combinação terapêutica para tratamento da doença de alzheimer | |
UY27348A1 (es) | Imidazotriazinas | |
ITRM20030213A0 (it) | Composizione farmaceutica per l'uso nella cura delle malattie psichiche e dei disturbi ad esse correlati. | |
DOP2003000657A (es) | Amidas de acidos 2-heteroarilcarboxilicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/02/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 19A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2710 DE 13-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |